Ad
Monday, 21 August 2017
AstraZeneca ups investment in messenger RNA drugs with Ethris deal
FRANKFURT (Reuters) - AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment